Accès ouvert
2026
article
OpenAlex
Sattva S. Neelapu, Olga Nikolajeva, Caron A. Jacobson
What is this summary about? This is a summary of a clinical study called ZUMA-5. The study looked at how well the cancer treatment axicabtagene ciloleucel (axi-cel) worked for people with indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma (FL) and marginal zone …
us, au
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Caron A. Jacobson, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi et autres
7028 Background: Axi-cel, autologous anti-CD19 CAR T-cell therapy, showed long-term survival and curative potential in R/R LBCL (ZUMA-1; Neelapu et al. Blood . 2023). Few studies have examined long-term outcomes beyond clinical trials. Here we report long-term real-world outcomes of axi-cel in …
us
(code pays fourni par la source)
2025
article
OpenAlex
John G. Gribben, M. Lia Palomba, Eve Limbrick-Oldfield, Madhu Palivela et autres
ZUMA-5 was the pivotal phase II single-arm trial (NCT03105336) that evaluated the efficacy and safety of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell thera...
us, fr
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Aung M. Tun, Matthew J. Frank, Madiha Iqbal, Alex F. Herrera et autres
Abstract Introduction: Axi-cel, an autologous anti-CD19 CAR T-cell therapy has shown high and durable response rates and a manageable safety profile among R/R FL pts in the ZUMA-5 trial (Jacobson et al. 2022; Neelapu et al. 2024). Evidence from real-world data showed …
us, nl, au
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, Narendranath Epperla et autres
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and …
us, fr
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, Narendranath Epperla et autres
Introduction: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) based on the Phase 2 ZUMA-5 trial in patients (pts) with R/R indolent non-Hodgkin lymphoma (iNHL; FL and marginal zone lymphoma [MZL]). With …
us, fr
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
John G. Gribben, Paola Ghione, Maria Lia Palomba, Markqayne D Ray et autres
Introduction: Axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy), led to durable responses in relapsed/refractory (R/R) follicular lymphoma (FL) in the pivotal ZUMA-5 trial. When 3-year efficacy data from ZUMA-5 were compared to the SCHOLAR-5 external control cohort (ASH …
gb, us, es, pt, fr
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Emmanuel Bachy, Sattva S. Neelapu, Julio C. Chávez, Ibrahim Yakoub‐Agha et autres
Introduction: Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is approved for adults with relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by ZUMA-5, a Phase 2, multicenter, single-arm study of axi-cel in patients with R/R indolent non-Hodgkin lymphoma. After …
fr, us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, Narendranath Epperla et autres
Introduction: ZUMA-5 is a multicenter Phase 2 study of axi-cel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL; follicular lymphoma [FL] and marginal zone lymphoma [MZL]). After a median of ≥3 years of …
us, fr
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Jason R. Westin, Caron A. Jacobson, Julio C. Chávez, Anna Sureda et autres
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The nearly 40% of patients with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], …
us, es, fr, de, au, gb, nl
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Jason R. Westin, Caron A. Jacobson, Julio C. Chávez, Anna Sureda et autres
TPS7578 Background: The nearly 40% of patients (pts) with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line (1L) standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H], vincristine [O], and prednisone [P]) and …
us, es, fr, de, au, gb, nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Jason R. Westin, Caron A. Jacobson, Julio C. Chávez, Anna Sureda et autres
International audience
us, es, fr, de, au, gb, nl
(code pays fourni par la source)